What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?
In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.
We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.
They explore:
The evolving payer evidence landscape in the US
Preferences for clinical and economic evidence by US payers
Key differences between the US and other global markets with regard to evidence, HEOR, and market access
Opportunities and challenges when launching new medicines/medical devices/diagnostics in the US
Innovative perspectives on evidence planning and strategy for the US market
US payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer survey
Podden och tillhörande omslagsbild på den här sidan tillhör
Petauri Evidence. Innehållet i podden är skapat av Petauri Evidence och inte av,
eller tillsammans med, Poddtoppen.
